following a full submission:
caplacizumab (Cablivi®) is accepted for use within NHSScotland.
Indication under review: Treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Caplacizumab, compared with placebo, decreased the time to platelet count response and reduced the risk of thrombotic thrombocytopenic purpura recurrence in adults receiving plasma exchange and immunosuppression for aTTP.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- caplacizumab (Cablivi)
- SMC ID:
- SMC2266
- Indication:
For the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
- Pharmaceutical company
- Sanofi
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 September 2020